Clinical trial · Observational
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY\* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ. PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and atypical ductal hyperplasia, a risk factor for developing cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gadavist | Drug | — | UNRESOLVED |
| Magnetic Resonance Imaging (MRI) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast Cancer patients
- description
- Adult, breast cancer patients with confirmed Ductal Carcinoma in Situ (DCIS) or atypical ductal hyperplasia (ADH)
- interventionNames
- Procedure: Magnetic Resonance Imaging (MRI)
- Drug: Gadavist
Primary outcomes (2)
- measure
- Comparison of ductal carcinoma in situ (DCIS)-optimized MRI quality
- timeFrame
- 1 month
- description
- Conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality will be used to determine the overall image quality for each MRI.
- measure
- Comparison of two DCIS-optimized MRIs for variability in enhancement levels for DCIS
- timeFrame
- 1 month
- description
- Conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality will be used to determine the overall image variability for each MRI.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Meets 1 of the following criteria:
* Patients at the University of California, San Francisco Breast Care Center meeting the following criteria:
* Biopsy proven ductal carcinoma in situ (DCIS) of the breast.
* Has undergone mammography within the past 60 days.
* ADH patients: over 18, no prior history of breast disease.
PATIENT CHARACTERISTICS:
* Referrals to this trial are through breast care clinicians only
* Not pregnant or nursing (or stopped nursing within the past 3 months)
* Negative pregnancy test
* No contraindication to MRI (e.g., implanted pacemaker, implanted ferromagnetic device, ferromagnetic aneurysm clip, severe claustrophobia, ocular metal fragments, or shrapnel injury)
PRIOR CONCURRENT THERAPY:
* More than 2 years since prior surgery to the ipsilateral breast (patient)
* No prior radiotherapy to the ipsilateral breast (patient)
* No prior cytotoxic regimens (patient)References
Publications (0)
Data not yet available